Cargando…

Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis

What is the impact of switching between biologics and biosimilars of adalimumab, etanercept, and infliximab on efficacy and safety for rheumatoid arthritis? A systematic review and network meta-analysis were performed to compare switching and non-switching groups of treatments. Pooled Risk Relative...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Oliveira Ascef, Bruna, Almeida, Matheus Oliveira, de Medeiros-Ribeiro, Ana Cristina, de Oliveira Andrade, Danieli Castro, de Oliveira Junior, Haliton Alves, de Soárez, Patrícia Coelho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444768/ https://www.ncbi.nlm.nih.gov/pubmed/37607959 http://dx.doi.org/10.1038/s41598-023-40222-5

Ejemplares similares

Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
por: Ascef, Bruna de Oliveira, et al.
Publicado: (2023)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
por: Ascef, Bruna O., et al.
Publicado: (2021)

Health technology assessment of biosimilars worldwide: a scoping review
por: Ascef, Bruna de Oliveira, et al.
Publicado: (2020)

Forecasting models for leprosy cases: a scoping review protocol
por: Oliveira Ascef, Bruna, et al.
Publicado: (2022)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

Mapping the characteristics, concepts and methodologies of matching-adjusted indirect comparison studies assessing pharmacological therapies in oncology: a scoping review protocol
por: Farinasso, Cecília Menezes, et al.
Publicado: (2023)

Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Switching of biological therapies in Brazilian patients with rheumatoid arthritis
por: de Lucena Valim, Juliana Miranda, et al.
Publicado: (2018)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Clinical Equivalence between Generic Versus Branded Antibiotics: Systematic Review and Meta-Analysis
por: Cotia, André, et al.
Publicado: (2023)

Benefits of Home-Based Exercise Training Following Critical SARS-CoV-2 Infection: A Case Report
por: Longobardi, Igor, et al.
Publicado: (2022)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Health Technology Assessment: informed by science or in the service of politics?
por: de Soárez, Patrícia Coelho
Publicado: (2021)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Different words for stroke: the same concept? an analysis of associated symptoms and intended reaction in Brazil
por: de Mélo Silva Júnior, Mário Luciano, et al.
Publicado: (2023)

Transcriptome analyses suggest that changes in fungal endophyte lifestyle could be involved in grapevine bud necrosis
por: Ribeiro, Thales Henrique Cherubino, et al.
Publicado: (2020)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics
por: Limdi, Jimmy K, et al.
Publicado: (2021)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Socioeconomic status and the incidence of non-central nervous system childhood embryonic tumours in Brazil
por: de Camargo, Beatriz, et al.
Publicado: (2011)

Determining reference ranges for immunological cells of healthy indigenous individuals from a region in Brazil
por: de Morais, Isa Rita Brito, et al.
Publicado: (2023)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Basal ganglia calcification as a putative cause for cognitive decline
por: de Oliveira, João Ricardo Mendes, et al.
Publicado: (2013)

Methylglyoxal Exacerbates Lipopolysaccharide-Induced Acute Lung Injury via RAGE-Induced ROS Generation: Protective Effects of Metformin
por: Medeiros, Matheus L, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis
por: Herndon, Thomas M., et al.
Publicado: (2023)

Systematic Review of Health Economic Evaluations of Diagnostic Tests in Brazil: How accurate are the results?
por: Oliveira, Maria Regina Fernandes, et al.
Publicado: (2017)

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review
por: Tieu, Carolyn, et al.
Publicado: (2018)

Chlorhexidine gel associated with papain in pulp tissue dissolution
por: Couto De Oliveira, Gabriel, et al.
Publicado: (2013)

Laryngotracheal separation in pediatric patients: 13-year experience in a reference service
por: Antunes, Letícia Alves, et al.
Publicado: (2019)

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
por: Cozijnsen, M. A., et al.
Publicado: (2017)

A importância de reconhecer a síndrome antifosfolípide na medicina vascular
por: Funke, Andreas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hqat9ucat97smnm65ju0kkogg5